Targeting Renal Purinergic Signaling for the Treatment of Lithium-induced NDI

靶向肾脏嘌呤信号传导治疗锂诱导的 NDI

• 批准号: 8195888
• 负责人: BELLAMKONDA K KISHORE
• 金额: --
• 依托单位: VA SALT LAKE CITY HEALTHCARE SYSTEM
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-01 至 2014-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8195888
• 关键词: Acute; Adverse effects; Affect; Agonist; Amiloride; Anxiety; Argipressin; Biological; Biological Models; Bipolar Disorder; Blood; Cardiovascular system; Cell Culture Techniques; Cells; Chemosensitization; Chronic; Clinical; Clinical Trials; Coagulation Process; Combined Modality Therapy; Conscious; Culture Media; Data; Dehydration; Development; Drug Delivery Systems; Duct (organ) structure; Elderly; Electrolytes; Equilibrium; Evaluation; Event; Formularies; Freedom; Functional disorder; Funding; Future; General Population; Genetic; Goals; Healthcare; Hypernatremia; Hypovolemia; Infusion procedures; Injection of therapeutic agent; Intervention; Intoxication; Investigation; Iraq; Kidney; Knock-out; Knockout Mice; Knowledge; Laboratories; Life; Liquid substance; Lithium; Major Depressive Disorder; Marines; Marketing; Mediating; Mental Depression; Methods; Mission; Modality; Modeling; Molecular; Morbidity - disease rate; Mus; Nature; Nephrogenic Diabetes Insipidus; Nucleotides; Outcome; P2Y2 receptor; PTGS2 gene; Pathway interactions; Patients; Pharmaceutical Preparations; Physiological; Plavix; Play; Post-Traumatic Stress Disorders; Prevalence; Purinoceptor; Rattus; Receptor Gene; Replacement Therapy; Reporting; Research; Resistance; Risk; Role; Safety; Screening procedure; Signal Transduction; Soldier; Staging; Substance abuse problem; Surveys; System; Techniques; Therapeutic; Therapeutic Agents; Therapeutic Uses; Tissue Sample; Tissues; Urine; V2 Receptors; Vasopressins; Veterans; Vietnam; War; Water; Wild Type Mouse; Work; abstracting; analog; base; clinical practice; clinically relevant; clopidogrel; design; extracellular; feeding; hemodynamics; high risk; improved; in vivo; infancy; inhibitor/antagonist; innovation; insight; meetings; mortality; novel; older patient; operation; prevent; purinoceptor P2Y4; receptor; research study; response; social; success; suicidal risk; urinary